Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05663398
Other study ID # IBF02-E
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 17, 2022
Est. completion date May 31, 2022

Study information

Verified date December 2022
Source Darnitsa Pharmaceutical Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Darfen 400, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by PrJSC "Pharmaceutical firm "Darnitsa" [Ukraine]) and Reference medicinal product (marketed medicinal product Nurofen® Forte Express, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by Reckitt Benckiser [Poland] S.A.) in healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date May 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. The subject is Caucasian & aged between eighteen to fifty years (18 - 50), both inclusive. 2. The subject is within the limits for his height & weight as defined by the body mass index range (18.5 - 30.0 Kg/m2). 3. The subject is willing to undergo the necessary pre- & post- medical examinations set by this study. 4. The results of medical history, physical examination, vital signs & conducted medical laboratory tests are normal as determined by the clinical investigator. 5. The subject tested negative for Hepatitis B (HBsAg), Hepatitis C (HCVAb), human immunodeficiency virus (HIV Ab). 6. There is no evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements. 7. The subject is able to understand and willing to sign the informed consent form. 8. For female subjects: a negative pregnancy test must be confirmed, and if sexually active, at least 4 weeks of highly effective contraceptive method must be used prior to IMP administration and throughout the study progress until last visit; highly effective methods comprise hormonal contraceptives, intrauterine devices IUDs, sexual abstinence or vasectomized partner (success of vasectomy was medically proven). For subjects using a hormonal contraceptive method, a barrier form of contraception should be combined with the hormonal contraception. 9. The subject kidney and liver (AST & ALT enzymes) functions tests are within normal range. 10. The subject has normal gastrointestinal, respiratory & cardiovascular systems. Exclusion Criteria: 1. Subject is a smoker or an ex-smoker with a non-smoking history of less than 6 months. 2. The subject has suffered an acute illness one week before dosing. 3. The subject has a history of or concurrent abuse of alcohol. 4. The subject has a history of or concurrent abuse of illicit drugs. 5. The subject has a history of hypersensitivity and/or contraindications to the study drug and any related compounds. 6. The subject has been hospitalized within three months before the study or during the study. 7. The subject is on special diet (for example subject is vegetarian). 8. The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two days before dosing and until 24 hours after dosing in all study periods. 9. The subject has taken a prescription medication within two weeks or even an over-the-counter product (OTC) within one week before dosing in each study period and any time during the study, unless otherwise judged acceptable by the clinical investigator. 10. The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before first dosing and any time during the study. 11. The subject has been participating in any clinical study (e.g., pharmacokinetics, bioavailability and bioequivalence studies) within the last 80 days prior to the present study. 12. The subject has donated blood within 80 days before first dosing. 13. The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, musculoskeletal or psychiatric diseases. 14. The subject has consumed drugs that may affect pharmacological or pharmacokinetic properties of Ibuprofen (for example: aspirin, celecoxib, ciprofloxacin, diclofenac, etodolac, fish oil, heparin, ketorolac, ketoprofen, naproxen, rivaroxaban, vitamin B12, vitamin C and vitamin D3) two weeks before dosing, during the study and two weeks after dosing. 15. Pregnant; with positive serum pregnancy test or breast-feeding female subjects. 16. The subject has a history of, or active, peptic ulceration, gastritis, esophagitis, gastrointestinal bleeding or perforation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Oral, a nonsteroidal anti-inflammatory drug
Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Oral, a nonsteroidal anti-inflammatory drug

Locations

Country Name City State
Jordan ACDIMA Center for Bioequivalence and Pharmaceutical Studies Amman

Sponsors (2)

Lead Sponsor Collaborator
Darnitsa Pharmaceutical Company ACDIMA Biocenter

Country where clinical trial is conducted

Jordan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum plasma concentration (Cmax) The Cmax value is based on the ibuprofen plasma concentration. Blood sampling for pharmacokinetic analysis covered up to 24 hours post-dose
Primary Area under the concentration-time curve from time zero to the last quantifiable concentration (t) The AUC0-t is the area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (t) and is based on the ibuprofen plasma concentration. Blood sampling for pharmacokinetic analysis covered up to 24 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1